Clinical trials: Cephalalgia
Dysmenorrhea, Headache, Migraine
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
- Conditions
- Dysmenorrhea, Headache, Migraine, Fatigue, Nausea
- Trial name
- NCT04091789
- Testing
- Pure Femme Tablets
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pure Green
Migraine Headache
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan to be used by patients to treat acute migraine treatment.
- Trial name
- NCT00530517
- Testing
- Intraject Sumatriptan
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Zogenix, Inc.
Pain
Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache
The purpose of this multi-center study is to assess the efficacy of headache relief of new paracetamol/caffeine formulation compared to placebo and ibuprofen in episodic tension-type headache (ETTH).
- Trial name
- NCT01842633
- Testing
- Paracetamol and Caffeine, Ibuprofen
- Where
- United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine, With or Without Aura
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
- Trial name
- NCT02873221
- Testing
- Ubrogepant, Usual Care
- Where
- 177 sites in United States
- Volunteers
- 1,254 people
- Sponsor
- Allergan
Migraine
A Randomized, Multicenter, Study for the prEvention and Acute Treatment of Migraine (REAL)
This is a randomized study for the prevention and acute treatment of migraine using open label nVNS and standard of care versus standard of care. .
- Trial name
- REAL (NCT03787238)
- Testing
- non-invasive vagus nerve stimulation
- Where
- 17 sites in Denmark, Germany and 3 more
- Sponsor
- ElectroCore INC
Migraine Disorders
An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)
This study will evaluate the exposure of sumatriptan after administration of TREXIMA (sumatriptan 85mg/naproxen sodium 500mg) followed by a subcutaneous IMITREX injection (4mg or 6mg) 2 hours later compared to administration of a…
- Trial name
- NCT00875784
- Testing
- TREXIMA™, IMITREX® (4mg), IMITREX® (6mg)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Migraine Headache
A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache
The purpose of this study is to determine if zonisamide is effective as a preventative medication for individuals with migraine headache.
- Trial name
- NCT00055484
- Testing
- zonisamide
- Where
- 13 sites in United States
- Volunteers
- 204 people
- Sponsor
- Elan Pharmaceuticals
Chronic Migraine, Headache
Study Using the ShiraTronics Migraine Therapy System
The purpose of this pilot study is to assess the preliminary safety and efficacy of the ShiraTronics Migraine Therapy System in prophylactic treatment of patients with refractory chronic migraine.
- Trial name
- RELIEV-CM (NCT05700318)
- Testing
- neurostimulator
- Where
- 4 sites in Australia
- Volunteers
- 40 people
- Sponsor
- ShiraTronics
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Migraine
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine
- Trial name
- NCT02629861
- Testing
- Fremanezumab
- Where
- 275 sites in United States, Canada and 7 more
- Volunteers
- 875 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
- Trial name
- NCT07816367
- Testing
- Elismetrep
- Where
- 72 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- TriGemX Bio, Inc.
Migraine
A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine
The purpose of this study is to determine a recommended dose of topiramate in participants with migraine (type of severe headache that occurs periodically and is often associated with nausea, vomiting, and constipation or…
- Trial name
- NCT01081795
- Testing
- Topiramate
- Where
- 29 sites in Japan
- Volunteers
- 387 people
- Sponsor
- Janssen Pharmaceutical K.K.
Migraine
A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
The purpose of this study is to evaluate the efficacy and safety of eptinezumab administered intravenously in participants experiencing an acute attack of migraine.
- Trial name
- RELIEF (NCT04152083)
- Testing
- Eptinezumab
- Where
- 57 sites in United States, Georgia
- Volunteers
- 485 people
- Sponsor
- H. Lundbeck A/S
Migraine
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101.
- Trial name
- NCT06728553
- Testing
- MTX101
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Manistee Therapeutics
Migraine
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.
- Trial name
- NCT03912337
- Testing
- Erenumab
- Where
- 28 sites in United States
- Volunteers
- 29 people
- Sponsor
- Amgen
Migraine
A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.
This is a double-blind randomised controlled study to evaluate the effectiveness of orally-dosed Palmitoylethanolamide (PEA) compared to placebo for reducing pain severity and duration of migraines in otherwise healthy…
- Trial name
- NCT05046522
- Testing
- Palmitoylethanolamide sold as Levagen +
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- RDC Clinical Pty Ltd
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine…
- Trial name
- NP101-009 (NCT00806546)
- Testing
- NP101
- Where
- 31 sites in United States
- Volunteers
- 514 people
- Sponsor
- NuPathe Inc.
Chronic Cluster Headache
REsponse to Combined SONS and ONS in Chronic Cluster headachE
The purpose of this study is to demonstrate the safe use of the PRIMUS System in subjects with chronic cluster headache. This is a single-centre, open label, prospective, first in human study to collect initial clinical data on…
- Trial name
- RESPONSE (NCT05868044)
- Testing
- PRIMUS
- Where
- Australia
- Volunteers
- 5 people
- Sponsor
- Salvia BioElectronics
Migraine
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007).
- Trial name
- NCT06680206
- Testing
- Rimegepant, Triptans
- Where
- United States
- Volunteers
- 1,395 people
- Sponsor
- Pfizer
Migraine Disorders
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet
The study is designed to investigate the information on safety and efficacy of naratriptan tablets on Japanese subjects with migraine headache during Japanese post-marketing surveillance period.
- Trial name
- NCT01376193
- Testing
- Naratriptan
- Volunteers
- 500 people
- Sponsor
- GlaxoSmithKline